| dc.contributor.author | Demir, Nazlım Aktuğ | |
| dc.contributor.author | Kölgelier, Servet | |
| dc.contributor.author | Özçimen, Serap | |
| dc.contributor.author | Aksöz, Selçuk | |
| dc.contributor.author | İnkaya, Ahmet Çağkan | |
| dc.date.accessioned | 2022-06-06T10:51:33Z | |
| dc.date.available | 2022-06-06T10:51:33Z | |
| dc.date.issued | 2012 | |
| dc.identifier.issn | 2147-673X | |
| dc.identifier.uri | http://dspace.adiyaman.edu.tr:8080/xmlui/handle/20.500.12414/3082 | |
| dc.description.abstract | Adefovir dipivoxil is an orally effective prodrug excreted unchanged in urine by glomerular filtration and tubular secretion. While it effectively suppresses hepatitis B virus replication, it may cause nephrotoxicity characterized by severe hypophosphatemia. In this report, we present a case of isolated hypophosphatemia due to long-term use of adefovir dipivoxil (10 mg/day). Due to the risk of hypophosphatemia with extended use, calcium and serum levels and symptoms suggesting nephrotoxicity should be followed in patients using adefovir dipivoxil for an extended period. | tr |
| dc.language.iso | en | tr |
| dc.publisher | Galenos Yayıncılık | tr |
| dc.subject | Adefovir | tr |
| dc.subject | Hypophosphatemia | tr |
| dc.subject | Adverse drug reaction | tr |
| dc.title | Hypophosphatemia Due to Adefovir Treatment | tr |
| dc.type | Article | tr |
| dc.contributor.authorID | 0000-0002-4703-0827 | tr |
| dc.contributor.authorID | 0000-0001-7027-5497 | tr |
| dc.contributor.authorID | 0000-0001-7943-8715 | tr |
| dc.contributor.department | Adiyaman State Hosp, Infect Dis Unit, | tr |
| dc.contributor.department | Adiyaman Univ, Fac Med, Dept Infect Dis & Clin Microbiol, | tr |
| dc.contributor.department | Konya Numune Hosp, Clin Infect Dis & Clin Microbiol | tr |
| dc.contributor.department | Hacettepe Univ, Fac Med, Dept Internal Med, Infect Dis Unit | tr |
| dc.identifier.volume | 1 | tr |
| dc.source.title | Mediterranean Journal Of Infection Microbes And Antimicrobials | tr |